 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- || Review, Journal: Biased regulation of glucocorticoid receptors signaling. (Pubmed Central) - Jul 16, 2023
Based on the bias regulation of GR, selective GR agonists and modulators (SEGRAMs) were developed to bias therapeutic outcomes toward expected outcomes (e.g., anti-inflammation and immunoregulation) by influencing GR-mediated gene expression. This paper provides a review of the bias regulation and mechanism of GR and the research progress of drugs.
- ||| BI 653048 / Boehringer Ingelheim
New P1 trial: Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects (clinicaltrials.gov) - Aug 25, 2014
P1, N=56, Completed, Sponsor: Boehringer Ingelheim
- ||| BI 653048 / Boehringer Ingelheim
New P1 trial: Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (clinicaltrials.gov) - Aug 15, 2014
P1, N=80, Completed, Sponsor: Boehringer Ingelheim
- ||| BI 653048 / Boehringer Ingelheim
Biomarker, New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers (clinicaltrials.gov) - Aug 15, 2014
P1, N=140, Completed, Sponsor: Boehringer Ingelheim